Cancer immunity derailed: PGE2 misconducts cDC1s
- PMID: 37315532
- DOI: 10.1016/j.immuni.2023.05.015
Cancer immunity derailed: PGE2 misconducts cDC1s
Abstract
Type 1 conventional dendritic cells (cDC1s) are critical for CD8+ T cell-mediated tumor control. In this issue of Immunity, Bayerl et al.1 expose a mechanism leading to cancer progression where prostaglandin E2 induces dysfunctional cDC1s, which cannot coordinate CD8+ T cell migration and expansion.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests N.B. is an extramural member of the Parker Institute for Cancer Immunotherapy (PICI), receives research funds from Regeneron, Antidote, and Dragonfly Therapeutics, and is on the advisory boards of Novartis, Rome Therapeutics, BreakBio, Carisma Therapeutics, Genotwin, the Cancer Research Institute, and on the Board of Directors for the American Association for Cancer Research (AACR).
Comment on
-
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses.Immunity. 2023 Jun 13;56(6):1341-1358.e11. doi: 10.1016/j.immuni.2023.05.011. Immunity. 2023. PMID: 37315536
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials